Aripiprazole Tablet
Product Images NDC 0615-8524

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 0615-8524). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ncs Healthcare Of Ky, Llc Dba Vangard Labs, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Formula (Aripiprazole 8524 8525 1)

Chemical structure of aripiprazole, depicting its molecular configuration including two chlorine atoms attached to a benzene ring, a piperazine ring, a butoxy linker, and a quinolinone moiety.*

FDA Label Image

Figure-1.jpg (Aripiprazole 8524 8525 10)

Line graph showing the change in YGTSS total tic score from baseline over 8 weeks of treatment for three groups: Aripiprazole low dose, Aripiprazole high dose, and placebo. The y-axis represents the least-squares mean change in tic score, and the x-axis represents weeks of treatment. Both Aripiprazole groups show a greater decrease in tic scores compared to placebo over time.*

FDA Label Image

Principal Display Panel (Aripiprazole 8524 8525 11)

Label for Aripiprazole Tablets, USP 2 mg oral tablets by NCS HealthCare of KY, LLC dba Vangard Labs. The label includes the product name, strength, dosage form, lot number, barcodes, manufacturer information (ScieGen for Dr. Reddy's), quantity of 30 tablets, and storage instructions. The label also contains multiple small barcoded sections with the same product information intended for packaging use.*

FDA Label Image

Principal Display Panel (Aripiprazole 8524 8525 12)

Aripiprazole Tablets USP 10 mg label from NCS HealthCare of KY, LLC dba Vangard Labs. The label includes barcodes, lot numbers, and handling instructions indicating storage at 25°C with allowable excursions. It features a calendar grid for logging received dates and times, with multiple smaller labels for individual tablets or packages each marked with 10 mg strength, lot number, and barcode.*

FDA Label Image

Figure-1.jpg (Aripiprazole 8524 8525 2)

A horizontal dot-and-whisker plot showing the effect of various drugs on the pharmacokinetics of Aripiprazole. The x-axis represents the fold change in Aripiprazole levels relative to a reference without interacting drugs, with data points for AUC and Cmax. Drugs listed include CYP3A4 inhibitors (ketoconazole), CYP2D6 inhibitors (quinidine), CYP3A4 inducers (carbamazepine), gastric acid blockers (famotidine), and others (valproate, lithium, lorazepam). The plot visualizes fold changes and 90% confidence intervals for each interaction.*

FDA Label Image

Figure-2.jpg (Aripiprazole 8524 8525 3)

A chart depicting the effect of various drugs on the pharmacokinetics (AUC and Cmax) of Aripiprazole. It shows fold changes with 90% confidence intervals for CYP3A4 inhibitors, CYP2D6 inhibitors, CYP3A4 inducers, gastric acid blockers, and other drugs relative to a reference without interacting drugs, illustrating their impact on Aripiprazole exposure.*

FDA Label Image

Figure-3.jpg (Aripiprazole 8524 8525 4)

A chart showing the effect of Aripiprazole on the pharmacokinetics (PK) of other drugs, with fold change and 90% confidence intervals for AUC and Cmax values of various drugs including dextromethorphan, warfarin, omeprazole, lamotrigine, valproate, lithium, lorazepam, venlafaxine, desmethylvenlafaxine, and escitalopram, relative to reference without interacting drug.*

FDA Label Image

Figure-4.jpg (Aripiprazole 8524 8525 5)

A pharmacokinetic (PK) chart titled "Aripiprazole Fold Change and 90% CI" showing fold changes in AUC and Cmax for special populations relative to a reference. Populations include CYP2D6 metabolizer status, gender, age groups, hepatic impairment (mild, moderate, severe), and severe renal impairment. The x-axis measures change relative to reference from 0.5 to 3.0 with plotted points and confidence intervals.*

FDA Label Image

Figure-5.jpg (Aripiprazole 8524 8525 6)

A pharmacokinetic chart illustrating fold changes and 90% confidence intervals in dehydro-aripiprazole levels under various conditions. Variables include CYP2D6 metabolizer status, gender, age groups, hepatic impairment levels, and severe renal impairment. The x-axis represents change relative to reference, while the y-axis shows AUC and Cmax values for each condition.*

FDA Label Image

Figure-6.jpg (Aripiprazole 8524 8525 7)

A Kaplan-Meier curve showing the proportion of subjects with relapse over 182 days from randomization comparing Aripiprazole and placebo. The X-axis shows days from randomization, and the Y-axis shows the proportion with relapse. Two lines represent Aripiprazole (solid) and placebo (dashed), with numbers of subjects at risk listed below the X-axis at various time points.*

FDA Label Image

Figure 7 (Aripiprazole 8524 8525 8)

A line graph depicting the proportion of patients with relapse over 182 days from randomization comparing Aripiprazole tablets to placebo. The x-axis shows days from randomization, and the y-axis shows the proportion with relapse. The graph includes the number of subjects at risk for each group at various time points.*

FDA Label Image

Figure 8 (Aripiprazole 8524 8525 9)

A Kaplan-Meier plot displaying the proportion of subjects with relapse over 364 days from randomization, comparing Aripiprazole to placebo. The x-axis shows days from randomization; the y-axis shows the proportion with relapse. Curves for Aripiprazole and placebo are shown with respective subject counts at risk below the x-axis.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.